In vitro susceptibility of Stenotrophomonas maltophilia isolates: Comparison of disc diffusion, Etest and agar dilution methods

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 4, 2004, Pages 604-608

  Nicodemo, A C ^a   Araujo, M R E ^b   Ruiz, A S ^b   Gales, A C ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Drug resistance; S. maltophilia; Susceptibility testing

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; POLYMYXIN B; TIMENTIN;

ANALYTICAL ERROR; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BRAZIL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DIFFUSION; DILUTION; DRUG EFFICACY; DRUG RESPONSE; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RELIABILITY; STANDARDIZATION; STENOTROPHOMONAS MALTOPHILIA;

ANTI-INFECTIVE AGENTS; COLONY COUNT, MICROBIAL; HUMANS; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; STENOTROPHOMONAS MALTOPHILIA;

EID: 11144346815     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh128     Document Type: Article

References (26)

1. Garrison, M. W., Anderson, D. E., Campbell, D. M. et al. (1996). Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrobial Agents and Chemotherapy 40, 2859-64.
2. Zhang, L., Li, X. Z. & Poole, K. (2000). Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrobial Agents and Chemotherapy 44, 287-93.
3. Li, X. Z., Zhang, L. & Poole, K. (2002). SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 46, 333-43.
4. Li, X. Z., Zhang, L., McKay, G. A. et al. (2003). Role of the acetyltransferase AAC(6′)-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. Journal of Antimicrobial Chemotherapy 51, 803-11.
5. National Committee for Clinical Laboratory Standards. (2000). Performance Standards for Disk Susceptibility Tests - Seventh Edition: Approved Standard M2-A7. NCCLS, Wayne, PA, USA.
6. National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA, USA.
7. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing - Twelfth Informational Supplement M100-S12. NCCLS, Wayne, PA, USA.
8. National Committee for Clinical Laboratory Standards. (1981). Performance Standards for Antimicrobic Disc Susceptibility Tests: Approved Standard M2-A2-S2. NCCLS, Wayne, PA, USA.
9. National Committee for Clinical Laboratory Standards. (2000). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters: Approved Standard M23-A2. NCCLS, Wayne, PA, USA.
10. Arpi, M., Victor, M. A., Mortensen, I. et al. (1996). In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS 104, 108-14.
11. Hohl, P., Frei, R. & Aubry, P. (1991). In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results. Diagnostic Microbiology and Infectious Disease 14, 447-50.
12. Yao, J. D. C., Louie, M., Louie, L. et al. (1995). Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia. Journal of Clinical Microbiology 33, 1428-30.
13. National Committee for Clinical Laboratory Standards. (1979). Performance Standards for Antimicrobial Disc Susceptibility Tests - Second Edition: Approved Standard ASM-2. NCCLS, Villanova, PA, USA.
14. Canton, R., Valdezate, S., Vindel, A. et al. (2003). Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with non cystic fibrosis isolates. Pediatric Pulmonology 35, 99-107.
15. Gales, A. C., Jones, R. N., Forward, K. R. et al. (2001). Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clinical Infectious Diseases 32, Suppl. 2, 104-13.
16. Valdezate, S., Vindel, A., Loza, E. et al. (2001). Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrobial Agents and Chemotherapy 45, 1581-4.
17. Tsiodras, S., Pittet, D., Carmeli, Y. et al. (2000). Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scandinavian Journal of Infectious Diseases 32, 651-6.
18. Gales, A. C., Reis, A. O. & Jones, R. N. (2001). Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. Journal of Clinical Microbiology 39, 183-90.
19. Bonfiglio, G., Cascone, C., Azzarelli, C. et al. (2000). Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. Journal of Antimicrobial Chemotherapy 45, 115-7.
20. Sanchez-Hernandez, J., Manzanares, M. A., Gutierrez Zufiaurre, M. N. et al. (1999). In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia. Revista Espanola de Quimioterapia 12, 234-6.
21. Ribera, A., Jurado, A., Ruiz, J. et al. (2002). In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagnostic Microbiology and Infectious Disease 42, 123-8.
22. Biedenbach, D. J., Croco, M. A., Barrett, T. J. et al. (1999). Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. European Journal of Clinical Microbiology and Infectious Diseases 18, 428-31.
23. Traub, W. H., Leonhard, B. & Bauer, D. (1998). Antibiotic susceptibility of Stenotrophomonas (Xanthomonas) maltophilia: comparative (NCCLS criteria) evaluation of antimicrobial drugs with the agar dilution and the agar disk diffusion (Bauer-Kirby) tests. Chemotherapy 44, 164-73.
24. Levin, A. S., Barone, A. A., Penço, J. et al. (1999). Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Infectious Diseases 28, 1008-11.
25. Muñoz, J. L., Garcia, M. I., Muñoz, S. et al. (1996). Activity of trimethoprim-sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. European Journal of Clinical Microbiology and Infectious Diseases 15, 879-82.
26. Giamarellos-Bourboulis, E. J., Karnesis, L. & Giamarellou, H. (2002). Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagnostic Microbiology and Infectious Disease 44, 259-63.